We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Fungal Infection Identified by Pathogen Detection Array Technology

By LabMedica International staff writers
Posted on 09 Feb 2016
Patients who are undergoing treatment for diseases such as cancer often face the added challenge of a compromised immune system, which can be challenging to both of their condition and the drugs used to treat it, leaving them vulnerable to various opportunistic infections.

A novel investigational technology has been developed that can rapidly identify elusive microorganisms which are not only life-threatening, but those caused by rare organisms are extremely difficult to isolate and identify.

Scientists at the University of Pennsylvania (Philadelphia, PA, USA) utilized a pathogen array technology referred to as PathoChip, comprised of oligonucleotide probes that can detect all the sequenced viruses as well as known pathogenic bacteria, fungi and parasites and family-specific conserved probes, thus providing a means for detecting previously uncharacterized members of a family. More...
The technology contains 60,000 probes that simultaneously test for all known viruses, as well as a variety of bacteria, fungi, helminths, and protozoa.

The investigators applied the PathoChip test to tissue samples of a patient with relapsed acute myelogenous leukemia (AML). The patient, a middle-aged man, had undergone chemotherapy for the cancer, a treatment that is well known to weaken the immune system, increasing susceptibility to infection. As a result, he developed an unknown fungal infection. The team rapidly identified a zygomycetous fungus, Rhizomucor, an otherwise challenge for the clinical laboratories, predominantly in the patient with acute myelogenous leukemia.

Erle Robertson, PhD, a professor and vice-chair for research in Otorhinolaryngology, said, “We've run many tests to see if we could identify pathogens in the laboratory, just to see if the PathoChip has efficacy in identifying a variety of organisms, and we were able to identify all infectious agents tested, but this was the first time we actually looked directly at a patient sample to identify a pathogenic agent. With this technology, out of 60,000 possibilities and probes that we used, in a little over 24 hours we were able to identify this particular fungi.” The study was published originally online on November 20, 2015, in the journal Cancer, Biology & Therapy.

Related Links:

University of Pennsylvania



Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.